Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma

Table 1 Baseline characteristics

Parameter	Number of participants (n = 66)
Mean age (yr)	53.3 ± 13.6
Sex
Male	55
Female	11
Maximum tumor diameter (cm)
≤ 5	27
5-10	26
> 10	13
Child-Pugh score
A	57
B7	9
BCLC stage
B	29
C	37
ECOG PS
0	46
1	20
Vascular invasion
Present	25
Absent	41
Portal vein invasion
Present	23
Absent	43
Extrahepatic metastasis
Present	16
Absent	50
HBV
Positive	54
Negative	12
HBV DNA (copies/mL)
> 2 × 103	30
≤ 2 × 103	36
Cirrhosis
Present	50
Absent	16
AFP (ng/mL)
≤ 100	26
> 100	40

AFP: Alpha-fetoprotein; HBV: Hepatitis B virus infection; BCLC: Barcelona Clinic Liver Cancer; ECOG PS: Eastern Cooperative Oncology Group performance status.

Table 2 Tumor response (modified Response Evaluation Criteria for Solid Tumors)

Best tumor response	Participants, n (%)
DCR, CR + PR + SD	58 (87.9)
ORR, CR + PR	28 (42.4)
CR	9 (13.6)
PR	19 (28.8)
SD	30 (45.5)
PD	8 (12.1)

All participants were treated with hepatic arterial infusion chemotherapy (oxaliplatin, 5-fluorouracil, and folinic acid) after transarterial chemoembolization combined with sorafenib for intermediate and advanced hepatocellular carcinoma. CR: Complete response; DCR: Disease control rate; PR: Partial response; SD: Stable disease; ORR: Objective response rate.

Table 3 Treatment-emergent and drug-related adverse events

Adverse event			Participants, n (%)
	Grade I	Grade II	Grade III	Grade IV
Hematological
Decreased platelet count	14 (21.2)	8 (12.1)	3 (4.5)	0 (0)
Decreased neutrophil count	15 (22.7)	11 (16.7)	2 (3.0)	0 (0)
Non-hematological
Elevated alanine	30 (45.5)	8 (12.1)	4 (6.1)	4 (6.1)
Elevated serum bilirubin	20 (30.3)	26 (39.4)	5 (7.6)	0 (0)
Nausea and vomiting	32 (48.5)	8 (12.1)	0 (0)	0 (0)
Pain	29 (43.9)	11 (16.7)	0 (0)	0 (0)
Fever	4 (6.1)	2 (3.0)	0 (0)	0 (0)
Diarrhea	10 (15.2)	6 (9.1)	0 (0)	0 (0)
Hand-foot skin reaction	7 (10.6)	16 (24.2)	4 (6.1)	0 (0)
Neurotoxicity	18 (27.3)	7 (10.6)	0 (0)	0 (0)

Data are the number of patients, with percentages in parentheses; all participants were treated with hepatic arterial infusion chemotherapy (oxaliplatin, 5-fluorouracil, and folinic acid) after transarterial chemoembolization combined with sorafenib for intermediate and advanced hepatocellular carcinoma.